Smart Finance APP reports that Genscript Bio (01548) announced on November 5, 2024, that Legend Biotech will present the latest data on the Micro Residual Disease (MRD) negativity rate from the Phase 3 CARTITUDE-4 trial, comparing the treatment of multiple myeloma patients with CARVYKTI (cilta-cel) and standard therapy (SoC) who have previously received 1–3 lines of treatment and are resistant to lenalidomide. The study evaluated patients who were resistant to lenalidomide after receiving 1–3 lines of treatment and will be presented in oral form at the 66th American Society of Hematology Annual Meeting in San Diego on December 9, 2024 (Monday) at 5:45 PM Pacific Time.

Data from CARTITUDE-4 supports the approvals by the US Food and Drug Administration and the European Commission earlier this year for the use of CARVYKTI in the treatment of relapsed or refractory multiple myeloma in adult patients who have previously received at least one line of treatment (LOT), including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and are resistant to lenalidomide. CARVYKTI is currently the first and only approved targeted BCMA CAR-T cell therapy for the treatment of multiple myeloma patients who have received at least one line of treatment. CARVYKTI is now commercially available in five countries globally, with over 4,000 patients treated.